Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia

Pharmacogenomics

Volumn 13, Issue 3, 2012, Pages 269-282

  Abraham, Ajay ^a   Varatharajan, Savitha ^a   Abbas, Salar ^a   Zhang, Wei ^b   Shaji, Ramachandran V ^a   Ahmed, Rayaz ^a   Abraham, Aby ^a   George, Biju ^a   Srivastava, Alok ^a   Chandy, Mammen ^a   Mathews, Vikram ^a   Balasubramanian, Poonkuzhali ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

acute myeloid leukemia; cytarabine; cytidine deaminase; drug resistance; polymorphisms

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENINE; CYTARABINE; CYTIDINE DEAMINASE; CYTOSINE; MESSENGER RNA; THYMINE;

3' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; INDIVIDUALIZATION; INTRON; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE REPEAT; NUCLEOTIDE SEQUENCE; PATIENT CARE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

3' UNTRANSLATED REGIONS; 5' UNTRANSLATED REGIONS; ADOLESCENT; ADULT; AGED; BASE SEQUENCE; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CYTARABINE; CYTIDINE DEAMINASE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HAPLOTYPES; HUMANS; INTRONS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; U937 CELLS; YOUNG ADULT;

ARA;

EID: 84863018501     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.149     Document Type: Article

References (48)

1. Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematology Am. Soc. Hematol. Educ. Program. 396-405 (2009).
2. Radich JP. Molecular classification of acute myeloid leukemia: are we there yet? J. Clin. Oncol. 26(28), 4539-4541 (2008).
3. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 92(11), 1519-1532 (2007). (Pubitemid 350144128)
4. Zwaan CM, Kaspers GJ. Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. Br. J. Haematol. 127(3), 264-279 (2004). (Pubitemid 39480693)
5. Galmarini CM, Thomas X, Calvo F et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br. J. Haematol. 117(4), 860-868 (2002). (Pubitemid 34639247)
6. Hubeek I, Stam RW, Peters GJ et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br. J. Cancer 93(12), 1388-1394 (2005). (Pubitemid 41752866)
7. Rustum YM, Preisler HD. Correlation between leukemic cell retention of 1-beta-d-arabinofuranosylcytosine 5́-triphosphate and response to therapy. Cancer Res. 39(1), 42-49 (1979). (Pubitemid 9090410)
8. Kufe D, Spriggs D, Egan EM, Munroe D. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 64(1), 54-58 (1984). (Pubitemid 14085726)
9. Chou TC, Arlin Z, Clarkson BD, Phillips FS. Metabolism of 1-beta-d-arabinofuranosylcytosine in human leukemic cells. Cancer Res. 37(10), 3561-3570 (1977). (Pubitemid 8198413)
10. Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics 10(10), 1657-1674 (2009).
11. Gaddis NC, Sheehy AM, Ahmad KM et al. Further investigation of simian immunodeficiency virus Vif function in human cells. J. Virol. 78(21), 12041-12046 (2004). (Pubitemid 39390788)
12. Cohen SS. The lethality of aranucleotides. Med. Biol. 54(5), 299-326 (1976). (Pubitemid 8011967)
13. Benhura MA. Metabolism of cytosine arabinoside in Tetrahymena pyriformis. Comp. Biochem. Physiol. B 80(4), 821-825 (1985).
14. Jahns-Streubel G, Reuter C, Auf Der Landwehr U et al. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood 90(5), 1968-1976 (1997). (Pubitemid 27377308)
15. Schroder JK, Seidelmann M, Kirch HC, Seeber S, Schutte J. Assessment of resistance induction to cytosine arabinoside following transfer and overexpression of the deoxycytidylate deaminase gene in vitro. Leuk. Res. 22(7), 619-624 (1998). (Pubitemid 28327465)
16. Braess J, Pfortner J, Kern W, Hiddemann W, Schleyer E. Cytidine deaminase-the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells. Ann. Hematol. 78(11), 514-520 (1999).
17. Schroder JK, Kirch C, Seeber S, Schutte J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br. J. Haematol. 103(4), 1096-1103 (1998). (Pubitemid 29012650)
18. Ciccolini J, Dahan L, Andre N et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J. Clin. Oncol. 28(1), 160-165 (2010).
19. Sugiyama E, Kaniwa N, Kim Sr et al. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin. Pharmacokinet. 49(8), 549-558 (2010).
20. Saccone S, Besati C, Andreozzi L, Della Valle G, Garattini E, Terao M. Assignment of the human cytidine deaminase (CDA) gene to chromosome 1 band p35-p36.2. Genomics 22(3), 661-662 (1994). (Pubitemid 24274003)
21. Demontis S, Terao M, Brivio M, Zanotta S, Bruschi M, Garattini E. Isolation and characterization of the gene coding for human cytidine deaminase. Biochim. Biophys. Acta 1443(3), 323-333 (1998). (Pubitemid 29023363)
22. Mercier C, Raynal C, Dahan L et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet. Genomics 17(10), 841-844 (2007). (Pubitemid 47462297)
23. Mahlknecht U, Dransfeld CL, Bulut N et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia 23(10), 1929-1932 (2009).
24. Ueno H, Kaniwa N, Okusaka T et al. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br. J. Cancer 100(6), 870-873 (2009).
25. Sugiyama E, Kaniwa N, Kim SR et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 25(1), 32-42 (2007). (Pubitemid 350003048)
26. Bhatla D, Gerbing RB, Alonzo TA et al. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br. J. Haematol. 144(3), 388-394 (2009).
27. Maring JG, Wachters FM, Slijfer M et al. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A C cytidine deaminase polymorphism. Eur. J. Clin. Pharmacol. 66(6), 611-617 (2010).
28. Sugiyama E, Lee SJ, Lee SS et al. Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene. Drug Metab. Pharmacokinet. 24(6), 553-556 (2009).
29. Mercier C, Dahan L, Ouafik L, Andre N, Ciccolini J. Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur. J. Clin. Pharmacol. 66(9), 959-960 (2010).
30. Giovannetti E, Tibaldi C, Falcone A, Danesi R, Peters GJ. Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing. J. Clin. Oncol. 28(14), e221-222; author reply e223-225 (2010).
31. Fitzgerald SM, Goyal RK, Osborne WR, Roy JD, Wilson JW, Ferrell RE. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum. Genet. 119(3), 276-283 (2006).
32. Ge Y, Jensen TL, Stout ML et al. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res. 64(2), 728-735 (2004). (Pubitemid 38120916)
33. Gilbert JA, Salavaggione OE, JI Y et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. 12(6), 1794-1803 (2006).
34. Pieters R, Loonen AH, Huismans DR et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 76(11), 2327-2336 (1990).
35. Klumper E, Pieters R, Kaspers GJ et al. In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Leukemia 9(11), 1864-1869 (1995).
36. D'argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, CA, USA (2009).
37. Hartford CM, Duan S, Delaney SM et al. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113(10), 2145-2153 (2009).
38. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005). (Pubitemid 40202029)
39. Purcell NB, Todd-Brown K, Thomas L et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559-575 (2007). (Pubitemid 47330214)
40. Galmarini CM, Thomas X, Graham K et al. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br. J. Haematol. 122(1), 53-60 (2003). (Pubitemid 36819338)
41. Jordheim LP, Nguyen-Dumont T, Thomas X, Dumontet C, Tavtigian SV. Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53. Drug Metab. Dispos. 36(12), 2419-2423 (2008).
42. Caronia D, Martin M, Sastre J et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin. Cancer Res. 17(7), 2006-2013 (2011).
43. Ribelles N, Lopez-Siles J, Sanchez A et al. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr. Drug Metab. 9(4), 336-343 (2008). (Pubitemid 351836423)
44. Hunt R, Sauna ZE, Ambudkar SV, Gottesman MM, Kimchi-Sarfaty C. Silent (synonymous) SNPs: should we care about them? Methods Mol. Biol. 578, 23-39 (2009).
45. Maring JG, Groen HJ, Wachters FM, Uges DR, De Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 5(4), 226-243 (2005). (Pubitemid 41131715)
46. Zwaan CM, Kaspers GJ, Pieters R et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 96(8), 2879-2886 (2000).
47. Yamada S, Hongo T, Okada S, Watanabe C, Fujii Y, Ohzeki T. Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia 15(12), 1892-1897 (2001). (Pubitemid 33114996)
48. Watanabe S, Uchida T. Expression of cytidine deaminase in human solid tumors and its regulation by 1 alpha,25-dihydroxyvitamin D3. Biochim. Biophys. Acta 1312(2), 99-104 (1996). (Pubitemid 26227439)